45 related articles for article (PubMed ID: 25722211)
1. BRAF and NRAS prognostic values in conjunctival melanoma: analysis and literature review.
Valentín-Bravo FJ; Pérez-Rodríguez Á; García-Álvarez C; García-Lagarto E; Saornil-Álvarez MA
Arq Bras Oftalmol; 2023; 86(5):e20230071. PubMed ID: 35544941
[TBL] [Abstract][Full Text] [Related]
2. The OSUMMER lines: A series of ultraviolet-accelerated NRAS-mutant mouse melanoma cell lines syngeneic to C57BL/6.
Murphy BM; Jensen DM; Arnold TE; Aguilar-Valenzuela R; Hughes J; Posada V; Nguyen KT; Chu VT; Tsai KY; Burd CJ; Burd CE
Pigment Cell Melanoma Res; 2023 Sep; 36(5):365-377. PubMed ID: 37341054
[TBL] [Abstract][Full Text] [Related]
3. A prognostic signature of G(2) checkpoint function in melanoma cell lines.
Omolo B; Carson C; Chu H; Zhou Y; Simpson DA; Hesse JE; Paules RS; Nyhan KC; Ibrahim JG; Kaufmann WK
Cell Cycle; 2013 Apr; 12(7):1071-82. PubMed ID: 23454897
[TBL] [Abstract][Full Text] [Related]
4. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
Vogel CJ; Smit MA; Maddalo G; Possik PA; Sparidans RW; van der Burg SH; Verdegaal EM; Heck AJ; Samatar AA; Beijnen JH; Altelaar AF; Peeper DS
Pigment Cell Melanoma Res; 2015 May; 28(3):307-17. PubMed ID: 25728708
[TBL] [Abstract][Full Text] [Related]
5. Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma.
Barisione G; Fabbi M; Gino A; Queirolo P; Orgiano L; Spano L; Picasso V; Pfeffer U; Mosci C; Jager MJ; Ferrini S; Gangemi R
JAMA Ophthalmol; 2015 Sep; 133(9):1013-21. PubMed ID: 26068448
[TBL] [Abstract][Full Text] [Related]
6. Polysaccharide hydrogel combined with mesenchymal stem cells promotes the healing of corneal alkali burn in rats.
Ke Y; Wu Y; Cui X; Liu X; Yu M; Yang C; Li X
PLoS One; 2015; 10(3):e0119725. PubMed ID: 25789487
[TBL] [Abstract][Full Text] [Related]
7. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.
Welsh SJ; Corrie PG
Ther Adv Med Oncol; 2015 Mar; 7(2):122-36. PubMed ID: 25755684
[TBL] [Abstract][Full Text] [Related]
8. Targeting β-catenin using XAV939 nanoparticle promotes immunogenic cell death and suppresses conjunctival melanoma progression.
Antony F; Kang X; Pundkar C; Wang C; Mishra A; Chen P; Babu RJ; Suryawanshi A
Int J Pharm; 2023 Jun; 640():123043. PubMed ID: 37172631
[TBL] [Abstract][Full Text] [Related]
9. The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma.
Youn GM; Case AG; Jarin T; Li B; Swarup A; Naranjo A; Bou-Khalil C; Yao J; Zhou Q; Hom ME; Rosenthal EL; Wu AY
Transl Vis Sci Technol; 2022 Jul; 11(7):23. PubMed ID: 35895055
[TBL] [Abstract][Full Text] [Related]
10. IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma.
Song D; Cismas S; Crudden C; Trocme E; Worrall C; Suleymanova N; Lin T; Zheng H; Seregard S; Girnita A; Girnita L
Oncogene; 2022 Jan; 41(4):600-611. PubMed ID: 34785779
[TBL] [Abstract][Full Text] [Related]
11. Process development and safety evaluation of ABCB5
Norrick A; Esterlechner J; Niebergall-Roth E; Dehio U; Sadeghi S; Schröder HM; Ballikaya S; Stemler N; Ganss C; Dieter K; Dachtler AK; Merz P; Sel S; Chodosh J; Cursiefen C; Frank NY; Auffarth GU; Ksander B; Frank MH; Kluth MA
Stem Cell Res Ther; 2021 Mar; 12(1):194. PubMed ID: 33741066
[TBL] [Abstract][Full Text] [Related]
12. Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference.
Smith JR; Pe'er J; Belfort RN; Cardoso F; Carvajal RD; Carvalho C; Coupland SE; Desjardins L; Francis JH; Gallie BL; Gombos DS; Grossniklaus HE; Heegaard S; Jager MJ; Kaliki S; Ksander BR; Maeurer M; Moreno E; Pulido JS; Ryll B; Singh AD; Zhao J; Parreira A; Wilson DJ; O'Brien JM
Transl Vis Sci Technol; 2019 Jan; 8(1):9. PubMed ID: 30652059
[TBL] [Abstract][Full Text] [Related]
13. Conjunctival melanoma and electrochemotherapy: preliminary results using 2D and 3D cell culture models in vitro.
Fiorentzis M; Katopodis P; Kalirai H; Seitz B; Viestenz A; Coupland SE
Acta Ophthalmol; 2019 Jun; 97(4):e632-e640. PubMed ID: 30548215
[TBL] [Abstract][Full Text] [Related]
14. Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.
Cao J; Heijkants RC; Jochemsen AG; Dogrusöz M; de Lange MJ; van der Velden PA; van der Burg SH; Jager MJ; Verdijk RM
Oncotarget; 2017 Aug; 8(35):58021-58036. PubMed ID: 28938534
[TBL] [Abstract][Full Text] [Related]
15. Expression of Multidrug Resistance Transporter ABCB5 in a Murine Model of Human Conjunctival Melanoma.
de Waard NE; Kolovou PE; McGuire SP; Cao J; Frank NY; Frank MH; Jager MJ; Ksander BR
Ocul Oncol Pathol; 2015 Apr; 1(3):182-189. PubMed ID: 25960995
[TBL] [Abstract][Full Text] [Related]
16. A Murine Model for Metastatic Conjunctival Melanoma.
de Waard NE; Cao J; McGuire SP; Kolovou PE; Jordanova ES; Ksander BR; Jager MJ
Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2325-33. PubMed ID: 25722211
[TBL] [Abstract][Full Text] [Related]
17. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
